Gleb Vladimirovich Simavonyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gleb Vladimirovich Simavonyan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Alexandrovich Galenko-Yaroshevsky
Kuban State Medical University
2 shared publications - Roman Alexeevich Murashko
Kuban State Medical University
2 shared publications - Anait V. Zelenskaya
Kuban State Medical University
1 shared publication - Andrey N. Gromov
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
1 shared publication - Andrey Vladimirovich Zadorozhniy
Rostov State Medical University
1 shared publication - E.M. I. Muhammad
Kuban State Medical University
1 shared publication
Latest Publications
- 16 October 2025
- Published by ECO-Vector LLC in Reviews on Clinical Pharmacology and Drug Therapy
- Vol. 23 (3) , 221-232
Typic adverse reactions from chemotherapy in cancer patients
The issues of chemotherapy remain the most difficult, because it is perhaps practically impossible to carry out drug therapy correctly, observing the main ethical principle of a doctor – do no harm. One of the main principles of chemotherapy is based on stopping cell replication, destroying their growth and vital activity, which is undoubtedly associated with an impact on healthy cells, the life cycle of which, depending on histological characteristics, may vary from several days to several weeks and months, which, in any case, implies an inevitable damaging effect on various organ and tissue systems. The more aggressive the chemotherapy, the more complex the combinations used, the greater the damaging consequences. Knowing the most vulnerable targets, the mechanisms of their development, it is possible to correct the most dangerous risks and prevent undesirable consequences. Accumulated experience with chemotherapy allows us to predict the most dangerous risks arising both during therapy, from chronic diseases that reduce quality of life, and after its completion, including delayed effects leading to death due to hidden, dangerous complications. Properly selected and timely complication prevention, comprehensive diagnostics of markers of pathological changes in vital organs, adjustments to therapy, and other measures are the fundamental principles of effective therapy. The main recommendations are regular visits to specialized physicians in related fields and patient compliance. Treatment for cancer patients does not end with their discharge from the hospital. Lifelong follow-up is required for patients who have completed therapy with a positive outcome.
- 16 October 2025
- Published by ECO-Vector LLC in Reviews on Clinical Pharmacology and Drug Therapy
- Vol. 23 (3) , 221-232
Typic adverse reactions from chemotherapy in cancer patients
The issues of chemotherapy remain the most difficult, because it is perhaps practically impossible to carry out drug therapy correctly, observing the main ethical principle of a doctor – do no harm. One of the main principles of chemotherapy is based on stopping cell replication, destroying their growth and vital activity, which is undoubtedly associated with an impact on healthy cells, the life cycle of which, depending on histological characteristics, may vary from several days to several weeks and months, which, in any case, implies an inevitable damaging effect on various organ and tissue systems. The more aggressive the chemotherapy, the more complex the combinations used, the greater the damaging consequences. Knowing the most vulnerable targets, the mechanisms of their development, it is possible to correct the most dangerous risks and prevent undesirable consequences. Accumulated experience with chemotherapy allows us to predict the most dangerous risks arising both during therapy, from chronic diseases that reduce quality of life, and after its completion, including delayed effects leading to death due to hidden, dangerous complications. Properly selected and timely complication prevention, comprehensive diagnostics of markers of pathological changes in vital organs, adjustments to therapy, and other measures are the fundamental principles of effective therapy. The main recommendations are regular visits to specialized physicians in related fields and patient compliance. Treatment for cancer patients does not end with their discharge from the hospital. Lifelong follow-up is required for patients who have completed therapy with a positive outcome.
- Open Access
- 5 November 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (3) , 324-336
Differential chemoproteomic analysis of RRS-1 candidate molecule and molecules of several nonsteroidal anti-inflammatory drugs
Background. To plan effective and safe pharmacotherapy for inflammation and pain, it is important to evaluate the mechanisms and spectrum of action of nonsteroidal anti-inflammatory drugs (NSAIDs), including their effects on human proteome.Objective: to identify and evaluate the most significant specific differences of candidate molecule RRS-1 (N-{(Z)-2-(1-methyl-1H-indol-3-yl)1-[(propylamino)carbonyl]vinyl}benzamide) from other NSAIDs through differential chemoreactome analysis.Material and methods. Chemoproteomic modeling of pharmacological effects of RRS-1 molecule and a number of well-known NSAIDs (diclofenac, nimesulide, ketorolac) on human proteome was carried out on the basis of numerical prediction algorithms over the space of heterogeneous feature descriptions, developed in the topological approach to recognition by Yu.I. Zhuravlev and K.V. Rudakov scientific school.Results. Significant differences in the effects of the studied molecules were found for 1232 proteins of human proteome. The features of assessing interactions of the studied molecules with 47 target proteins, which most distinguished the effects of RRS-1 molecule from all others were identified. RRS-1 could activate adenosine and dopamine receptors, cannabinoid receptor 2 and GABAA receptor to a greater extent than other molecules. Activation of these receptors corresponded to anti-inflammatory, anti-nociceptive and neuroprotective effects. RRS-1 could preferably inhibit a number of pro-inflammatory proteins, receptor bradykinin 1, metabotropic glutamate receptor 5, matrix metalloproteinases 8, 9, 12, and blood coagulation factor X. Additionally, RRS-1 molecule showed preferable inhibition of a number of kinases targeted in antitumor and anti-inflammatory therapy. RRS-1, less than other studied molecules, interacted with the receptors of vitamin D3, thyroid hormone, acetylcholine, cannabinoids and opioids, orexin, and various metabolic enzymes, which is important in assessment of the safety of using drugs based on this molecule. RRS-1 characteristically exhibited a moderate profile of antivitamin action: the total score of vitamin and mineral loss (7.4±3.7) was significantly less in comparison to diclofenac (11.7±4.5) and was actually on the same level as nimesulide (6.9±3.7) and ketorolac (6.7±3.6).Conclusion. Chemoreactomic and chemoproteomic profiling of RRS-1 candidate molecule provided pre-experimental assessments of its efficacy and safety through modeling interactions with the human proteome.
- 5 November 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (3) , 324-336
Open AccessDifferential chemoproteomic analysis of RRS-1 candidate molecule and molecules of several nonsteroidal anti-inflammatory drugs
Background. To plan effective and safe pharmacotherapy for inflammation and pain, it is important to evaluate the mechanisms and spectrum of action of nonsteroidal anti-inflammatory drugs (NSAIDs), including their effects on human proteome.Objective: to identify and evaluate the most significant specific differences of candidate molecule RRS-1 (N-{(Z)-2-(1-methyl-1H-indol-3-yl)1-[(propylamino)carbonyl]vinyl}benzamide) from other NSAIDs through differential chemoreactome analysis.Material and methods. Chemoproteomic modeling of pharmacological effects of RRS-1 molecule and a number of well-known NSAIDs (diclofenac, nimesulide, ketorolac) on human proteome was carried out on the basis of numerical prediction algorithms over the space of heterogeneous feature descriptions, developed in the topological approach to recognition by Yu.I. Zhuravlev and K.V. Rudakov scientific school.Results. Significant differences in the effects of the studied molecules were found for 1232 proteins of human proteome. The features of assessing interactions of the studied molecules with 47 target proteins, which most distinguished the effects of RRS-1 molecule from all others were identified. RRS-1 could activate adenosine and dopamine receptors, cannabinoid receptor 2 and GABAA receptor to a greater extent than other molecules. Activation of these receptors corresponded to anti-inflammatory, anti-nociceptive and neuroprotective effects. RRS-1 could preferably inhibit a number of pro-inflammatory proteins, receptor bradykinin 1, metabotropic glutamate receptor 5, matrix metalloproteinases 8, 9, 12, and blood coagulation factor X. Additionally, RRS-1 molecule showed preferable inhibition of a number of kinases targeted in antitumor and anti-inflammatory therapy. RRS-1, less than other studied molecules, interacted with the receptors of vitamin D3, thyroid hormone, acetylcholine, cannabinoids and opioids, orexin, and various metabolic enzymes, which is important in assessment of the safety of using drugs based on this molecule. RRS-1 characteristically exhibited a moderate profile of antivitamin action: the total score of vitamin and mineral loss (7.4±3.7) was significantly less in comparison to diclofenac (11.7±4.5) and was actually on the same level as nimesulide (6.9±3.7) and ketorolac (6.7±3.6).Conclusion. Chemoreactomic and chemoproteomic profiling of RRS-1 candidate molecule provided pre-experimental assessments of its efficacy and safety through modeling interactions with the human proteome.